- World rank, all time
- #26,225 of 42,892
- Rank in Canada
- #560 of 896
- Research works
- 156 ▲ 164% vs 2013–17
- Citations
- 2.4k 15.1 per fractional work
- Top-10% rate
- 17.7% record average 16.5%
- Open access
- 46% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 4.5×. Every wedge is a field page.
- Economics, Econometrics and Finance 4.5×
- Immunology and Microbiology 3.2×
- Medicine 3.0×
- Biochemistry, Genetics and Molecular Biology 2.7×
- Decision Sciences 1.9×
- Mathematics 1.7×
- Neuroscience 1.3×
- Physics and Astronomy 0.8×
- Pharmacology, Toxicology and Pharmaceutics 0.6×
- Computer Science 0.5×
- Health Professions 0.4×
- Chemistry 0.2×
- Social Sciences 0.2×
- Psychology 0.1×
- Business, Management and Accounting 0.1×
- Agricultural and Biological Sciences 0.0×
- Arts and Humanities 0.0×
- Environmental Science 0.0×
- Engineering 0.0×
Which keywords describe research at Roche (Canada)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Lymphoma, Rituximab, Immunotherapy, Targeted Therapy, PET Imaging, Chemotherapy, Cost-effectiveness Analysis and Health Utility Measures.
- Neurodegeneration
- Quality Assurance
- PD-1 and PD-L1
- Glycosylation
- Radiotherapy
- ALK Inhibitors
- Antiphospholipid Syndrome
- Tumor Regression
- Cancer Immunotherapy
- Biomarkers
- Autoantibodies
- Precision Medicine
- Genetic Pathogenesis
- Gene Expression Profiling
- Prognostic Factors
- Cost-effectiveness Analysis
- Epidemiology
- Targeted Therapy
- Immunotherapy
- Inflammation
- Lymphoma
- Rituximab
- Quality of Life
- Chemotherapy
- PET Imaging
- Health Utility Measures
- Classification
- Molecular Profiling
- Hodgkin's Lymphoma
- Clinical Trials
- Breast Cancer
- CAR T Cells
- Chimeric Antigen Receptor
- Tumor Microenvironment
- Systemic Lupus Erythematosus
- EGFR Mutations
- Dosimetry
- Immune Checkpoint Blockade
- Predictive Modeling
- Metastatic Breast Cancer
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Lymphoma5▲ 48×2 topics
- Inflammation4▲ 2.9×17 topics
- Rituximab4▲ 41×4 topics
- Immunotherapy4▲ 8.2×10 topics
- Quality of Life4▲ 4.1×3 topics
- Targeted Therapy3▲ 26×4 topics
- Chemotherapy3▲ 7.8×9 topics
- Epidemiology3▲ 1.38×17 topics
- PET Imaging3▲ 32×3 topics
- Cost-effectiveness Analysis3▲ 58×1 topic
- Health Utility Measures3▲ 58×1 topic
- Prognostic Factors3▲ 11×8 topics
- Classification3▲ 10×2 topics
- Gene Expression Profiling3▲ 58×2 topics
- Molecular Profiling3▲ 48×2 topics
- Genetic Pathogenesis3▲ 85×1 topic
- Hodgkin's Lymphoma3▲ 85×1 topic
- Precision Medicine3▲ 9.6×6 topics
- Clinical Trials2▲ 6.0×5 topics
- Autoantibodies2▲ 16×4 topics
- Breast Cancer2▲ 14×5 topics
- Biomarkers2▲ 4.8×6 topics
- CAR T Cells2▲ 43×1 topic
- Cancer Immunotherapy2▲ 21×2 topics
- Chimeric Antigen Receptor2▲ 43×1 topic
- Tumor Regression2▲ 30×2 topics
- Tumor Microenvironment2▲ 6.8×5 topics
- Antiphospholipid Syndrome2▲ 60×1 topic
- Systemic Lupus Erythematosus2▲ 54×1 topic
- ALK Inhibitors2▲ 40×1 topic
- EGFR Mutations2▲ 40×1 topic
- Radiotherapy2▲ 6.7×4 topics
- Dosimetry1▲ 34×2 topics
- Glycosylation1▲ 21×2 topics
- Immune Checkpoint Blockade1▲ 21×1 topic
- PD-1 and PD-L11▲ 21×1 topic
- Predictive Modeling1▲ 8.6×2 topics
- Quality Assurance1▲ 14×3 topics
- Metastatic Breast Cancer1▲ 38×2 topics
- Neurodegeneration1▲ 7.6×4 topics
Which research topics does Roche (Canada) publish most on?
By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, Lymphoma Diagnosis and Treatment, CAR-T cell therapy research and Systemic Lupus Erythematosus Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 3 works
- 2 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 3 works
- 3 CAR-T cell therapy research Oncology 2 works
- 4 Systemic Lupus Erythematosus Research Rheumatology 2 works
- 5 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
- 6 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 7 Advanced Radiotherapy Techniques Radiation 1 works
- 8 Complex Systems and Decision Making Management Science and Operations Research 1 works
- 9 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
- 10 Pharmaceutical Economics and Policy Economics and Econometrics 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Roche (Canada)'s research output changed?
Output in 2018–2022 was 164% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Mississauga
- Nortel (Canada)
- Kellogg's (Canada)
- Hatch (Canada)
- Smiths Detection (Canada)
- Intertek (Canada)
- Trillium Health Centre
- College of Family Physicians of Canada
- General Electric (Canada)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.